Research and Evidence
Espansione's positioning rests on published, peer-reviewed science rather than marketing claims. The evidence base spans dry eye disease and meibomian gland dysfunction, the company's foundation, and now extends into the back of the eye with dry age-related macular degeneration. This page is the entry point to that body of work; deeper pages cover the publication library, clinical trials and the mechanism-of-action literature.
Recognition in international guidelines
The most significant external validation is the inclusion of low-level light therapy, the LM™ LLLT (PBM) modality delivered on eye-light®, in the TFOS DEWS III Management and Therapy Report (TFOS DEWS III, 2025, American Journal of Ophthalmology). DEWS III is the leading international consensus on dry eye, and it recognises photobiomodulation as beneficial across all three of its driver groups: the tear film, the eyelids and the ocular surface. See what DEWS III is and how light therapy fits.
Head-to-head clinical trials
Comparative claims should rest only on head-to-head data, and several randomised controlled trials provide it in meibomian gland dysfunction. LM™ LLLT improved symptom scores and tear meniscus height more than OPE™ IPL at two-week follow-up (Giannaccare et al., 2022, Cornea). Combined OPE™ IPL plus LM™ LLLT on eye-light® was superior to an IPL-only comparator at eighteen-month follow-up (Leite et al., 2025). Combined therapy bettered IPL-only competitor devices on lipid layer thickness and symptoms (Castro et al., 2023), and improved tear breakup time and symptoms more than sodium hyaluronate drops (Meduri et al., 2022).
Extending into the retina
In the posterior segment, early studies examined photobiomodulation for intermediate dry AMD, reporting safety, tolerability and short-term functional and anatomical signals (Borrelli et al., 2024, Ophthalmology and Therapy; Viggiano et al., 2025, Eye). These have since been reinforced by the 12-month, multicentre, randomised, double-masked DRUSEN trial, which found significant drusen reduction and a visual acuity benefit versus sham, with no treated eye progressing to neovascular AMD (Iovino et al., 2026, British Journal of Ophthalmology). See dry AMD and clinical trials.
How we frame evidence
Espansione distinguishes on-label from off-label use, notes that clearances vary by region, and makes no superiority claim without head-to-head evidence. Where the literature is still developing, that is stated plainly.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.